RecruitingPhase 2NCT07154264

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Principal Investigator: Niu
West China Hospital
Intervention: DZD8586(drug)
Enrollment: 66 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2030

Study locations (15)

Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Peking University Third Hospital, Beijing, Beijing Municipality, China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Yichang Central People's Hospital, Yichang, Hubei, China
Hunan Cancer Hospital, Changsha, Hunan, China
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07154264 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials